ClinicalTrials.gg
RecruitingNCT05614739FORAGER-1Updated Nov 4, 2026

FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3

A Phase 1 interventional study of Vepugratinib and Pembrolizumab in Urinary Bladder Neoplasms, Neoplasm Metastasis and Ureteral Neoplasms, sponsored by Eli Lilly and Company. Recruiting at 83 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2023; still recruiting 3 years 10 months later.
Updated Nov 4, 20263 sites added2 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
677
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Urinary Bladder Neoplasms by Eli Lilly and Company — 4 open to participants now, 5 under way, 1 of them phase 3. Urinary Bladder Neoplasms · Eli Lilly and Company.

Planned enrollment
Largest of 11
677 · median 355
Started
2023
the only one that year
Phase 1
5 of 14
2 open now
Registered
9th of 14
by date

Among the 14 studies in Urinary Bladder Neoplasms by Eli Lilly and Company, this one has the largest planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2023, is one of 5 in phase 1, and was the 9th registered.

Urinary Bladder Neoplasms

1,800 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

4 of the 14 studies in Urinary Bladder Neoplasms by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Urinary Bladder Neoplasms by Eli Lilly and Company, or all of them as a file.
02

Study summary

The main purpose of this study is to learn more about the safety, side effects, and effectiveness of Vepugratinib by itself or when it is combined with other medicines that treat cancer. Vepugratinib may be used to treat cancer of the cells that line the urinary system and other solid tumor cancers that have a change in a particular gene (known as the FGFR3 gene). Study participation could last up to approximately 6 years, depending on which part of the study you join.

Read the detailed description

This is an open-label, multi-center, phase 1 study in participants with FGFR3-altered advanced solid tumor malignancy including metastatic urothelial cancer (UC), muscle-invasive bladder cancer (MIBC), and low grade intermediate risk non-muscle-invasive bladder cancer (LG IR NMIBC). The study will be conducted in 2 phases. Phase 1a will assess safety, tolerability, and pharmacokinetics of Vepugratinib to determine the optimal dose for further expansion. Phase 1b will include dose expansion cohorts to evaluate the efficacy and safety of Vepugratinib as monotherapy or in combinations with other medicines that treat cancer.

03

Conditions studied

  • Urinary Bladder Neoplasms
  • Neoplasm Metastasis
  • Ureteral Neoplasms

Keywords

  • Bladder Cancer
  • Bladder Urothelial Carcinoma
  • Urinary Bladder Cancer
  • Urinary Tract Cancer
  • Renal Pelvis Cancer
  • Ureter Cancer
  • Non-Muscle Invasive Bladder Cancer
  • Muscle Invasive Bladder Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cohort A1, C1, D1, and D2: Locally advanced or solid tumor with a qualifying FGFR3 alteration.
  • Cohort A2, B2, B5 and B7: Urothelial cancer (UC) that is locally advanced or metastatic with a qualifying FGFR3 genetic alteration.
  • Cohorts B1 and B4: Urothelial cancer that is locally advanced or metastatic and have received prior erdafitinib.
  • Cohort B6: Muscle Invasive Bladder Cancer with a qualifying FGFR3 alteration.
  • Cohort B7: Urothelial cancer that is locally advanced or metastatic with a qualifying FGFR3 genetic alteration and expression of human epidermal growth factor receptor 2 ().
  • Cohort B8: Low Grade Intermediate Risk Non-Muscle Invasive Bladder cancer and a qualifying FGFR3 genetic alteration.
  • Measurability of disease:

    • Cohort A1, D1, and D2: Measurable or non- as defined by v 1.1 (RECIST v1.1).
    • Cohorts A2, B1, B2, B4, B5, B7, and C1: Measurable disease required as defined by RECIST v1.1.
    • Cohort B8: Baseline disease which includes at least 1 lesion.
  • Have an (ECOG) performance status of:

    • 0 or 1 for Cohorts A1, A2, B5, B6, B7, and B8.
    • Less than or equal to 2 for Cohorts B1, B2, B4, C1, DI and D2.
  • Cohort B6: Must be eligible for radical cystectomy plus pelvic lymph node dissection and agree to undergo curative intent standard radical cystectomy plus pelvic lymph node dissection.

Exclusion criteria

Exclusion Criteria:

  • Participants with primary central nervous system (CNS) .
  • Untreated or uncontrolled .
  • Current evidence of corneal keratopathy or retinal disorder. Individuals with asymptomatic ophthalmic conditions may be eligible.
  • Any serious unresolved toxicities from prior therapy.
  • Significant cardiovascular disease.
  • Prolongation of the corrected for heart rate using Fridericia's formula (QTcF).
  • Active uncontrolled systemic infection or other medical conditions.
  • Participants who are pregnant, lactating, or plan to breastfeed during the study or within 6 months of the last dose of study treatment. Participants who have stopped breastfeeding may be enrolled.
  • Cohort D1 only:

    • Have had renal transplantation.
    • Have a known history of nephrotic syndrome.
    • Have uncontrolled fluid overload, including clinically significant ascites, pleural effusion, or peripheral edema.
    • Have uncontrolled hypertension.
    • Are on hemodialysis or similar.
  • Cohort D2 only:

    • Have a history of:
    • Ventricular tachycardia or ventricular fibrillation.
    • Hypertrophic obstructive cardiomyopathy unless managed concurrently with atrial fibrillation.
    • Wolff-Parkinson-White syndrome.
    • Second- or third-degree atrioventricular block unless a functioning pacemaker is in place.
    • Heart rate less than (\<) 50 bpm.
    • Have any of these medical conditions:
    • Severe respiratory insufficiency.
    • Sleep apnea syndrome.
    • Myasthenia gravis.
    • Acute narrow-angle glaucoma.
    • Active liver disease or clinically significant hepatic impairment.
    • History of myopathy or rhabdomyolysis with any HMG-CoA reductase inhibitor.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
677 participants (estimated)

Study arms

  • Experimental
    Phase 1a: Cohort A1 Vepugratinib Monotherapy Dose Escalation

    Vepugratinib administered orally

    Drug: Vepugratinib

  • Experimental
    Phase 1a: Cohort A2 Vepugratinib Monotherapy Dose Optimization

    Vepugratinib administered orally

    Drug: Vepugratinib

  • Experimental
    Phase 1b: Cohort B1, B2, B4, C1, and D1 Vepugratinib Monotherapy Dose Expansion

    Vepugratinib administered orally

    Drug: Vepugratinib

  • Experimental
    Phase 1b: Cohort B5 Vepugratinib Plus Pembrolizumab Plus Enfortumab Vedotin

    Vepugratinib administered orally in combination with pembrolizumab administered IV and enfortumab vedotin administered IV

    Drug: Vepugratinib · Drug: Pembrolizumab · Drug: enfortumab vedotin

  • Experimental
    Phase 1b: MIBC Cohort B6 Vepugratinib Plus Pembrolizumab Plus Enfortumab Vedotin

    Vepugratinib administered orally in combination with pembrolizumab administered IV and enfortumab vedotin administered IV

    Drug: Vepugratinib · Drug: Pembrolizumab · Drug: enfortumab vedotin

  • Experimental
    Experimental: Phase 1b: Cohort B7 Vepugratinib Plus Trastuzumab Deruxtecan

    Vepugratinib administered orally in combination with trastuzumab deruxtecan administered IV

    Drug: Vepugratinib · Drug: Trastuzumab Deruxtecan

  • Experimental
    Phase 1b: NMIBC Cohort B8 Vepugratinib Monotherapy Dose Expansion

    Vepugratinib administered orally

    Drug: Vepugratinib

  • Experimental
    Phase 1b: Cohort D2 (Drug to Drug Interaction)

    Vepugratinib Plus Midazolam Plus Digoxin Plus Rosuvastatin (Lead-In Only) followed by Vepugratinib Monotherapy Vepugratinib administered orally Midazolam with digoxin with rosuvastatin administered orally once per cycle for 2 cycles.

    Drug: Vepugratinib · Drug: Midazolam · Drug: Digoxin · Drug: Rosuvastatin

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    Time frame: Up to Approximately 30 Months or 2.5 Years

  2. Pharmacokinetics (PK) of Vepugratinib: Area Under the Concentration versus Time Curve (AUC)

    Time frame: Up to 2 Months

  3. PK of Midazolam, Rosuvastatin, and Digoxin Administered Alone and in the Presence of Vepugratinib: Area Under the Concentration versus Time Curve (AUC[0-inf])

    Time frame: Up to 2 Months

  4. Complete Response Rate (CRR) in Participants with Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG IR NMIBC)

    Time frame: Up to approximately 24 months or 5 years

Secondary outcomes

  1. Change from Baseline in Bladder-Related Symptoms, Measured by Functional Assessment of Cancer Therapy - Bladder (FACT-Bl) Subscale (BlCS)

    Time frame: Cycle 1 Day 1, Cycle 2 Day 1, and Cycle 3 Day 1 (28 Day Cycles)

  2. Change from Baseline in Physical Function, Measured by FACT- Physical Well-Being Scale (PWB) Subscale

    Time frame: Up to Approximately 30 Months or 2.5 Years

  3. Event-Free Survival (EFS) in Participants with Muscle Invasive Bladder Cancer (MIBC)

    Time frame: Up to approximately 30 months or 2.5 years

07

Study locations

82 of 83 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Jun 2027, 53 months after the start.

Of 80 industry-sponsored phase 1 interventional studies under Urinary Bladder Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's planned 53 months is above that.

Counting every sponsor, half of 145 studies reached it within 43 months; a quarter within 29 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2022
First posted
Nov 14, 2022
StartActual
Jan 12, 2023
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2027
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added, 2 sites removed
Show 3 added (1 China, 1 Germany, 1 Israel)
  • Zhejiang Provincial People's Hospital · Hangzhou, China
  • Universitaetsklinikum Bonn · Bonn, Germany
  • Sheba Medical Center · Tel HaShomer, Israel
Show 2 removed
  • Zhejiang Provincial People's Hospital · Zhejiang, China
  • Sheba Medical Center · Tel Litwinsky, Israel
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    3 sites added, 2 sites removed
    Show 3 added (1 China, 1 Germany, 1 Israel)
    • Zhejiang Provincial People's Hospital · Hangzhou, China
    • Universitaetsklinikum Bonn · Bonn, Germany
    • Sheba Medical Center · Tel HaShomer, Israel
    Show 2 removed
    • Zhejiang Provincial People's Hospital · Zhejiang, China
    • Sheba Medical Center · Tel Litwinsky, Israel
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05614739
Responsible party
Sponsor
First posted
Nov 14, 2022
Start date
Jan 12, 2023
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Contact
LillyTrials@Lilly.com
1-317-615-4559
Physicians interested in becoming principal investigators please contact
Contact
clinical_inquiry_hub@lilly.com
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vepugratinib

Start the discussion